Last week, a panel of Alzheimer’s disease researchers and thought leaders from the Alzheimer’s Disease Biomarker Expert Working Group published their recommendations for the inclusion of biomarkers in clinical studies of the disease. According to the group, a number of currently studied biomarkers have sufficient evidence and validation that warrant further use in clinical trials, in particular because they offer greater precision than cognitive assessment tools, better select patients for enrollment, and reduce study time. See the press release for more details.
